The great pivot to AI compute, and a mid-cap identity crisis

If you spend enough time looking at the fringes of the Hong Kong market in 2026, you start to notice a recurring theme: the desperate, sometimes brilliant, and often very expensive quest for a new narrative. We are watching mid-cap companies rewrite their entire corporate DNA in real-time, because in today's market, if you aren't an AI or digital infrastructure play, what are you even doing?

The most striking moves right now are the structural pivots happening in legacy industries. Take Dynasty Digital (0451.HK). Until very recently, they were known as GCL New Energy. But in late June, they officially rebranded, signaling a total departure from traditional solar energy into the nebulous but highly lucrative-sounding world of "energy digitalization," backing up the new narrative with the acquisition of 20 million shares through their trust in July. Then there’s ITC Properties (0199.HK). What does a traditional real estate developer do when the old models stall? They pivot to generative AI, naturally. Mid-July saw them bring in a veteran capital markets operator as co-chairman, a move immediately followed by an ambitious memorandum to build a massive 1-gigawatt green AI computing center in Nantong. It’s the ultimate 2026 pivot.

But chasing the platform shift has a very real cost, as Qingsong Health (2661.HK) is currently discovering. The company has been aggressively pitching itself as an "AI-native health base"—which sounds great in an investor deck. The reality, however, is that training proprietary AI models in the medical vertical is violently expensive. In July, they issued a profit warning for the first half of 2026, expecting losses of up to 70 million RMB, explicitly citing the heavy R&D burden of their AI ambitions. Building the moat is currently burning the runway.

While some are chasing algorithms, others are simply engineering growth the old-fashioned way: M&A. TCL Electronics (1070.HK) is shelling out 5.6 billion HKD to fully absorb its affiliated air conditioning business. It’s a brute-force consolidation play that is already pointing to a massive 40% to 56% bump in adjusted net profits for the first half of the year. Over in the infrastructure sector, Zhejiang Expressway (0576.HK) just secured regulatory approval to absorb Zhenyang Development, pushing forward with complex corporate restructuring alongside strong Q1 earnings from its securities arm. And hovering above it all, the iShares A50 (2823.HK) ETF continues to act as the default barometer for anyone trying to index these broader macroeconomic shifts across the border.

Still, away from the aggressive rebrands and consolidations, some companies are just focusing on shipping actual products. HUTCHMED (0013.HK) locked down a crucial conditional approval in China for its gastric cancer drug in early July. Zhaoke Ophthalmology-B (6622.HK) is executing a similar playbook, getting its presbyopia drug YUVEZZI greenlit in regional hubs like Macau and Hainan. Add in the steady July share buybacks from Tongguan Gold (0340.HK) as it rides the commodity cycle, and the quiet endurance of traditional Cantonese dining operator Palace Banquet Holdings (1703.HK), and you get a perfect snapshot of a market in transition. Some are desperately trying to build the future, while others are just focused on surviving the present.